Finance

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

The company will be adding a new manufacturing site to its NJ campus for the drug Adstiladrin.

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in radiopharmaceutical production and distribution.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Marcel Botha, CEO of 10XBeta, discusses finding a balance between the need for cost-efficiency and the need to build domestic manufacturing capacity for essential medical devices.

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, identifies innovative strategies and solutions for addressing the rising cost of medications and improving patient access.

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, explores practical steps pharmaceutical executives can take to foster better collaboration within their organizations, as well as with external partners like providers and pharmacies.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective financing rounds.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology therapies, respectively.

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics areas.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in pharma investing.

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.